NO784192L - Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika - Google Patents
Fremgangsmaate til fremstilling av avgiftede preparater av cytostatikaInfo
- Publication number
- NO784192L NO784192L NO784192A NO784192A NO784192L NO 784192 L NO784192 L NO 784192L NO 784192 A NO784192 A NO 784192A NO 784192 A NO784192 A NO 784192A NO 784192 L NO784192 L NO 784192L
- Authority
- NO
- Norway
- Prior art keywords
- chloroethyl
- oxo
- oxazaphosphorinane
- acid
- salt
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- 230000001085 cytostatic effect Effects 0.000 title description 26
- 239000000824 cytostatic agent Substances 0.000 title description 24
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims description 15
- 229960001101 ifosfamide Drugs 0.000 claims description 15
- 229940006193 2-mercaptoethanesulfonic acid Drugs 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- 159000000000 sodium salts Chemical class 0.000 claims description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 9
- 229960004397 cyclophosphamide Drugs 0.000 claims description 7
- 229960000875 trofosfamide Drugs 0.000 claims description 7
- ZSZKJARKHWCBJK-UHFFFAOYSA-N 2-[[3-(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-yl]amino]ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCNP1(=O)OCCCN1CCCl ZSZKJARKHWCBJK-UHFFFAOYSA-N 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229950008275 sufosfamide Drugs 0.000 claims description 4
- 150000001447 alkali salts Chemical class 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- MRIMWDXKBILRPB-UHFFFAOYSA-N O=P1NCCCO1 Chemical compound O=P1NCCCO1 MRIMWDXKBILRPB-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 13
- 210000003932 urinary bladder Anatomy 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001635 urinary tract Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- COSZWAUYIUYQBS-UHFFFAOYSA-B hexapotassium hexasodium 3-carboxy-3-hydroxypentanedioate 2-hydroxypropane-1,2,3-tricarboxylate hydrate Chemical compound O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[K+].[K+].[K+].[K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O COSZWAUYIUYQBS-UHFFFAOYSA-B 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- OKVLRTXOHOBONS-UHFFFAOYSA-N 2-methyl-3-sulfanylpropane-1-sulfonic acid Chemical compound SCC(C)CS(O)(=O)=O OKVLRTXOHOBONS-UHFFFAOYSA-N 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- OBDVFOBWBHMJDG-UHFFFAOYSA-N 3-mercapto-1-propanesulfonic acid Chemical compound OS(=O)(=O)CCCS OBDVFOBWBHMJDG-UHFFFAOYSA-N 0.000 description 1
- HMEJBVOVTCTWRG-UHFFFAOYSA-N 6-sulfanylhexane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCCCS HMEJBVOVTCTWRG-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- JYCULSYEFRCGNR-UHFFFAOYSA-N O=P1OC=CC=N1 Chemical class O=P1OC=CC=N1 JYCULSYEFRCGNR-UHFFFAOYSA-N 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- ZQRHGLVWSWEITI-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinin-2-amine Chemical compound ClCCN(CCCl)P1(=O)OC=CC=N1 ZQRHGLVWSWEITI-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2756018A DE2756018C2 (de) | 1977-12-14 | 1977-12-14 | Verwendung von Salzen von Mercaptoalkansulfonsäuren |
| DE2827625 | 1978-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO784192L true NO784192L (no) | 1979-06-15 |
Family
ID=25773277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO784192A NO784192L (no) | 1977-12-14 | 1978-12-13 | Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika |
Country Status (6)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA851062B (en) * | 1984-03-01 | 1985-11-27 | Asta Werke Ag Chem Fab | Salts of oxazaphosphorine derivatives and process for their production |
| US5244920A (en) * | 1985-04-15 | 1993-09-14 | Schering Spa | Pharmaceutical compositions having therapeutical activity based on mercaptoethansulphonic arginine salt |
| IT1185551B (it) * | 1985-04-15 | 1987-11-12 | Schering Spa | Composizioni farmaceutiche a base di acido mercaptoetansolfonico ad attivita' terapeutica,derivati salini organici dell'acido mercaptoetansolfonico utili per tali composizioni e relativo procedimento di preparazione |
| DE58900183D1 (de) * | 1988-03-19 | 1991-08-29 | Asta Pharma Ag | Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung. |
| JPH01174407U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1988-05-26 | 1989-12-12 | ||
| DE4342091A1 (de) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
| US6197831B1 (en) * | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US6077838A (en) * | 1999-06-08 | 2000-06-20 | Bionumerik Pharmaceuticals, Inc. | Method of treating hangover |
| WO2001049822A2 (en) * | 1999-12-29 | 2001-07-12 | Sergei Mikhailovich Zenovich | Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| US6245815B1 (en) * | 2000-04-15 | 2001-06-12 | Bionumerik Pharmaceuticals, Inc. | Method of treating alcoholism and complications resulting therefrom |
| US6291441B1 (en) * | 2000-09-27 | 2001-09-18 | Frederick H. Hausheer | Method of treating inflammatory bowel disorders |
| US6352979B1 (en) * | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
| EA008776B1 (ru) * | 2002-09-05 | 2007-08-31 | Бхарат Сирумс Энд Вэксинс Лтд. | Жидкая стабильная композиция оксазафосфорина с месной |
| US7025998B2 (en) | 2003-05-30 | 2006-04-11 | Rotta Research Laboratorium S.P.A. | Phytoestrogens and probiotic for women's health |
| WO2005032515A1 (en) * | 2003-10-01 | 2005-04-14 | Baxter International Inc. | New use, pharmaceutical preparations as well as a process for their production |
| JP4936898B2 (ja) * | 2003-12-17 | 2012-05-23 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | ジスルフィド類の合成方法 |
| US20060063742A1 (en) * | 2004-09-21 | 2006-03-23 | Hausheer Frederick H | Method of treatment for or protection against lymphedema |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1119721A (en) * | 1965-05-07 | 1968-07-10 | Ucb Sa | Mucolytic mercapto-sulphonates |
-
1978
- 1978-12-06 US US05/967,000 patent/US4220660A/en not_active Expired - Lifetime
- 1978-12-06 EP EP78101583A patent/EP0002495B1/de not_active Expired
- 1978-12-07 DK DK553978A patent/DK154608C/da not_active IP Right Cessation
- 1978-12-07 FI FI783756A patent/FI783756A7/fi unknown
- 1978-12-13 JP JP15906678A patent/JPS54101432A/ja active Granted
- 1978-12-13 NO NO784192A patent/NO784192L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0002495A1 (de) | 1979-06-27 |
| JPS6154006B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1986-11-20 |
| JPS54101432A (en) | 1979-08-10 |
| DK154608C (da) | 1989-05-08 |
| US4220660A (en) | 1980-09-02 |
| DK154608B (da) | 1988-12-05 |
| EP0002495B1 (de) | 1984-02-15 |
| DK553978A (da) | 1979-06-15 |
| FI783756A7 (fi) | 1979-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO784192L (no) | Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika | |
| US20030232793A1 (en) | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders | |
| George et al. | Metabolism of isoprenaline in the intestine | |
| PT1339411E (pt) | ''utilização de ácido zoledrónico para tratamento da dor'' | |
| US12325705B2 (en) | Small molecules for the treatment of primary cancer and cancer metastasis | |
| BR0010257A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados | |
| Lavigne et al. | The treatment of experimental peritonitis with intraperitoneal betadine solution | |
| CA2104868C (en) | Method and products for treating the eye | |
| US5385726A (en) | Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one | |
| US4218471A (en) | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | |
| EP0542807A1 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one | |
| Key et al. | THE LOCAL USE OF SULFANILAMIDE, SULFAPYMDINE AND SULFAMETHYLTHIAZOL | |
| CA2580759C (en) | Method and composition for treating patients undergoing kidney dialysis | |
| EA022880B1 (ru) | Способы лечения с применением длительной непрерывной инфузии белиностата | |
| CA1117015A (en) | Process for producing detoxified pharmaceutical products containing a cytostatically active alkylating agent | |
| RU2703735C1 (ru) | Фармацевтическая композиция, содержащая DHMEQ или его аналоги | |
| EP0783884A1 (en) | Preventive and remedy for diarrhea | |
| US6197831B1 (en) | Method of treating septic shock | |
| JP2004523518A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| US20040086536A1 (en) | Therapeutic agents and treatment kits for hypertrophic pyloric stenosis | |
| SU1657190A1 (ru) | Способ профилактики аутоиммунного орхита после оперативного лечени крипторхизма | |
| US20010041744A1 (en) | Angiogenesis inhibitors | |
| MX2007003177A (es) | Metodo de tratamiento o proteccion contra linfedema. | |
| RU2022100706A (ru) | Способ лечения инсульта с применением трициклического производного | |
| Stage et al. | VALUE OF CHEMOTHERAPY IN OVARIAN MALIGNANCIES |